SUBSCRIBE
SUBSCRIBE

Phase I

Policy
Biopharma Update on the Novel Coronavirus: July 31
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 31, 2020.
July 30, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: July 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
July 29, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: July 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.
July 24, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: July 20-24
It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.
July 24, 2020
 · 
8 min read
 · 
Mark Terry
Drug Development
Research Roundup: Progress on COVID-19 Vaccines and More
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
July 23, 2020
 · 
7 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
July 23, 2020
 · 
4 min read
 · 
Editorial Staff
Courtesy of Jer123/Getty Images
Drug Development
NIH Pushing Large-Scale, Organized COVID-19 Trials
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
July 23, 2020
 · 
4 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
July 21, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
AstraZeneca, Oxford Post Positive Phase I Data for COVID-19 Vaccine Candidate
AstraZeneca’s COVID-19 vaccine candidate induced significant immune responses in the majority of patients following a single dose in a Phase I study. The preventative medication also proved to be fairly safe, study results showed.
July 20, 2020
 · 
3 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: July 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
July 20, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10
June 14, 2024
 · 
4 min read
Drug Development
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
June 14, 2024
 · 
6 min read
Drug Development
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
June 14, 2024
 · 
13 min read
Drug Development
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 13, 2024
 · 
9 min read
Drug Development
ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC
June 13, 2024
 · 
2 min read
Drug Development
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
June 13, 2024
 · 
5 min read
Drug Development
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
June 13, 2024
 · 
5 min read
Drug Development
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
June 13, 2024
 · 
7 min read
Drug Development
LG Chem company and AVEO Oncology Announce LG Chem’s First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S.
June 13, 2024
 · 
4 min read
Drug Development
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
June 13, 2024
 · 
3 min read
Drug Development
New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain
June 13, 2024
 · 
5 min read
Drug Development
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
June 12, 2024
 · 
7 min read
Drug Development
Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment
June 12, 2024
 · 
4 min read
Drug Development
Zumutor Biologics Announces Dosing of First Patient with ZM008, a First-in-Class Anti LLT1 Antibody
June 12, 2024
 · 
5 min read
Drug Development
Ensem Therapeutics Announces Achievement of Milestone Following Entry of Small Molecule CDK2 Inhibitor into Clinical Trials for Solid Tumors
June 12, 2024
 · 
2 min read
Drug Development
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion TrialSix additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in this trial
June 12, 2024
 · 
3 min read
Drug Development
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes & Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
June 12, 2024
 · 
12 min read
Drug Development
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
June 12, 2024
 · 
2 min read
Drug Development
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
June 12, 2024
 · 
2 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
June 12, 2024
 · 
4 min read
Load More